[1] Kovesdy CP, Ahmadzadeh S, Anderson JE, et al.Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease[J]. Kidney International, 2008, 73(11): 1296-1302. [2] Block GA, Klassen PS, Lazarus JM, et al.Mineralmetabolism, mortality, and morbidity in maintenance hemodialysis[J]. J Am Soc Nephrol, 2004, 15(8): 2208-2218. [3] Mustafar R, Mohd R, Miswan NA, et al.The effect of calcium with or without calcitriol supplementation on renal function in patients with hypovitaminosis d and chronic kidney disease[J]. Biophysical Journal, 2014, 75(2): 785-792. [4] Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)[J]. Kidney Int Suppl, 2017,7: 1-59. [5] Tentori F, Blayney MJ, Albert JM, et al.Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J]. Am J Kidney Dis, 2008, 52(3): 519-530. [6] Coyne DW, Goldberg S, Faber M, et al.A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD[J]. Clin J Am Soc Nephrol, 2014, 9(9): 1620-1626. [7] 张雪琴,庄晶,王喻,等. 帕立骨化醇和骨化三醇治疗血液透析患者继发性甲状旁腺功能亢进症的疗效比较[J]. 中华肾脏病杂志,2018,34(10):778-780. [8] Tonbul HZ, Solak Y, Atalay H, et al.Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study[J]. Renal Failure, 2012, 34(3): 297-303. [9] de Francisco AL, Izquierdo M, Cunningham J, et al. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet[J]. Nephrology Dialysis Transplantation, 2008, 23(9): 2895-2901. [10] D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients[J]. Kidney Int Suppl, 2003, (85): S73-S78. [11] 徐方,沈渝,齐永灵. 低钙透析液联合骨化三醇冲击治疗维持性血液透析合并继发性甲状旁腺功能亢进症疗效观察[J]. 海南医学,2016,27(14):2286-2288. [12] 陈小军,付慧,潘丽丽,等. 低钙透析液联合骨化三醇冲击治疗维持性血液透析合并继发性甲状旁腺功能亢进症的疗效[J]. 南昌大学学报(医学版),2012,52(8):78-79. |